Skip to content

Polyphenols and Insulin Resistance

INFLUENCE OF POLYPHENOLS ON OXIDATIVE STRESS IN HEALTHY INDIVIDUALS WITH HIGH METABOLISM RISK: RELATIONSHIP WITH THE MECHANISMS OF INSULIN RESISTANCE

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01478841
Acronym
POLYOXRESIST
Enrollment
44
Registered
2011-11-23
Start date
2008-10-31
Completion date
2012-01-31
Last updated
2012-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteers, Insulin Resistance, Type 2 Diabetes (T2D)

Keywords

insulin resistance, type 2 diabetes (T2D), cardiovascular complications, polyphenolic compounds derived from red grape marc extracts, oxidative stress

Brief summary

Diet and nutrition play an essential role in the development and the clinical expression of the most common health problems. Overeating and obesity induce oxidative stress, which has been proposed to be a pathogenic mechanism leading to insulin resistance, type 2 diabetes (T2D) and associated cardiovascular complications. The main objective of the proposed research is to evaluate the beneficial effects of polyphenolic compounds derived from red grape marc extracts on the cascade of events leading from overeating to oxidative stress and insulin resistance. For that, we will study free radicals production, inflammatory markers, adipokines, mitochondrial function, insulin sensitivity and energy substrate utilization in healthy volunteers at risk for insulin resistance and T2D (1st degree relatives of T2D patients with associated overweight). These volunteers will be randomized between a placebo and a polyphenol group for 9 weeks. The demonstration of the beneficial effects of polyphenols will be sensitized by high-fructose feeding for the last 6 days of the protocol.

Interventions

2 capsules of 0.5 gram to be taken at the beginning of breakfast and dinner (2g/day) fructose : dose of 3 g/kg/day from D57 to D62 in the form of a 20% solution taken during the three main meals

DRUGplacebo

2 capsules of 0.5 gram to be taken at the beginning of breakfast and dinner (2g/day) fructose : dose of 3 g/kg/day from D57 to D62 in the form of a 20% solution taken during the three main meals

Sponsors

University Hospital, Montpellier
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
30 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* Absence of anti HIV or anti hepatitis C antibodies and of HBS antigen. * Acceptable biological assessment of the hepatic and renal functions (γGT, ALAT, ASAT \< 3 times the normal value and serum creatinine \<150 micromol/l). * Age between 30 and 55 years. * Fasting plasma glucose \<110 mg/dl and absence of any anti-diabetic treatment * No regular physical activity (Voorips index \< 9) * Absence of any drug treatment in progress and during the last 2 months * Subjects with at least one 1st degree relative with T2D and with a body mass index between 25 and 35 kg/m² and a waist measurement \>94 cm for males, and \>80 cm for females. * Normal ionogram (sodium 135 - 145 mmol/l, potassium 3,5 - 4,5 mmol/l). * Normal ferritin level (75 - 300 ng/ml) * hs-CRP \<8 mg/l. * Absence of arterial hypertension (systolic pressure \<140 mmHg and diastolic pressure \<90 mmHg). * Non smoker or former smoker (quit smoking \>1 year). * Alcohol consumption \<30 g/day.

Exclusion criteria

* Hyperthermia (T°\>38°c) * Subject deprived of freedom by a court or administrative order * Major protected by the law * Subject who is in a period of relative exclusion due to his/her participation to another protocol or for whom the annual maximum amount of allowances of 3 811.23 € is reached. * Subject who has been treated with anti-coagulants, anti-inflammatory drugs, b-blockers or insulin during the last month. * Subject who cannot be subjected to muscle biopsy. * Allergy to the anaesthetic * Woman in age to procreate and not taking any oral or intra-uterine contraception

Design outcomes

Primary

MeasureTime frame
Peripheral insulin-sensitivity6 weeks

Secondary

MeasureTime frame
biochemical parameters6 weeks

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026